Prof. Rosario Osta, PhD in Genetics at the University of Zaragoza (1996). She is a Research Staff member (Full Professor) of Zaragoza University (UNIZAR). She is the Head of the “LAGENBIO: Teragen and Regeneragen” of the Institute of Aragón (IIS) in Zaragoza, Spain and it is part of the CIBERNED. She has an international reputation of more than 16 years on the field of Amyotrophic Lateral Sclerosis. She is co-founder of neuroscience network in IIS Aragon. She is focused in the search of prognostic and diagnostic biomarkers in patients of ALS. Also, she has focused on innovate therapy in ALS murine model and the results were patented and licensed to industry. She has been a keynote speaker in numerous meetings and national and international scientific conferences. She is responsible for more than 14 large projects and industry contracts. Prof. Osta has published more than 90 peer-reviewed scientific publications and has 8 patents. Total number of citations in ISI Web-of-Knowledge: 2052 and 2.955 in Google Scholar. Her h- Index is: 26 (WoS), 33 (GSch.), i10=64
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.